Lumateperone low dose

Phase 3

Intra-Cellular Therapies, Inc. (ITCI)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

ITCIPhase 3

Lumateperone low dose Phase 3 Est. Readout

Lumateperone low dose• Irritability Associated With Autism Spectrum Disorder160

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

2 competitors in Irritability Associated With Autism Spectrum Disorder

View Full Landscape

Drug Information

Target Indication

Irritability Associated With Autism Spectrum Disorder

Clinical Trial

NCT06690398

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ITCI

Intra-Cellular Therapies, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

LumateperonePhase 3

Major Depressive Disorder

Lumateperone high dosePhase 3

Irritability Associated With Autism Spectrum Disorder

ITI-007 (Lumateperone)Phase 3

Bipolar Depression

ITI-007Phase 3

Schizophrenia

Lumateperone 42 mgPhase 3

Schizophrenia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts